

Comprehensive Quality by Design in Pharmaceutical Development and Manufacture

Topical Conference at the 2010 AIChE Annual Meeting

**Salt Lake City, Utah, USA
7-12 November 2010**

ISBN: 978-1-61782-146-2

Printed from e-media with permission by:

Curran Associates, Inc.
57 Morehouse Lane
Red Hook, NY 12571



Some format issues inherent in the e-media version may also appear in this print version.

Copyright© (2010) by AIChE
All rights reserved.

Printed by Curran Associates, Inc. (2010)

For permission requests, please contact AIChE
at the address below.

AIChE
3 Park Avenue
New York, NY 10016-5991

Phone: (203) 702-7660
Fax: (203) 775-5177

www.aiche.org

Additional copies of this publication are available from:

Curran Associates, Inc.
57 Morehouse Lane
Red Hook, NY 12571 USA
Phone: 845-758-0400
Fax: 845-758-2634
Email: curran@proceedings.com
Web: www.proceedings.com

TABLE OF CONTENTS

(51a) Scale Independent Approach for Drug Product Development by High Shear Granulation Process	1
<i>Gavin K. Reynolds, Bindhu Gururajan, Jonathan Sutch, James Kraunsoe</i>	
(51b) A Quality by Design Approach to Scale-up of the Melt-Spray-Congel Multiparticulate Process	3
<i>Andrew Prpich, Pankaj Doshi, Louis Topper</i>	
(51c) Scale-up of High Shear Wet Granulation of Active Formulations Using a Dimensional Analysis Approach	4
<i>Intan Munirah Hamdan, William R. Ketterhagen</i>	
(51d) A Regulators Perspective On the Evaluation and Control of Ingredient Quality	6
<i>Steven Wolfgang</i>	
(51e) Toward a More Reliable USP Dissolution Testing Apparatus II	7
<i>Yimin Wang, Piero Armenante</i>	
(51f) Using Qualitative Models to Capture and Demonstrate Process Understanding	8
<i>Ian Houson</i>	
(51g) Characterization of Tablet Attritional Forces in a Friability Tester and Film Coating Pan Using DEM	9
<i>Rahul Bharadwaj, William R. Ketterhagen, Bruno C. Hancock</i>	
(108a) Implementation of Novel Integrated Pharmaceutical Processes: A Model-Based Approach	10
<i>Alicia Román Martínez, Rafiqul Gani, John M. Woodley</i>	
(108b) Design Space of Pharmaceutical Processes Using Data-Driven Based Methods	11
<i>Fani Boukouvala, Fernando J. Muzzio, Marianthi G. Ierapetritou</i>	
(108c) Model Based Control of Drug Substance Particle Size to Ensure Drug Product Uniformity	14
<i>Jon Hilden, Mark Schrad, Jessica T. Sloan, Jennifer Kuehne-Willmore, Timothy Kramer</i>	
(108d) Modeling the Roll Compaction Process Using Finite Element Analysis	15
<i>Ariel Muliadi, Carl R. Wassgren, James D. Litster</i>	
(108e) Application of Model Based Drug Substance Particle Size Control in Drug Product Development	17
<i>Mark Schrad, Jon Hilden, Jessica T. Sloan, Jennifer Kuehne-Willmore</i>	
(108f) Investigation of a Tablet Coating Process Using a Multi-Model Simulation Approach	18
<i>Daniele Suzzi, Gregor Toschkoff, Daniel Machold, Johannes Khinast</i>	
(170a) Quality by Design for Generic Drugs: Overview	19
<i>Robert A. Lionberger</i>	
(170b) Quality by Design in Pharmaceutical Development	20
<i>Yatindra Joshi</i>	
(170c) QbD for Generic Drugs: A Case Study for Immediate-Release Products	21
<i>Zhigang Sun</i>	
(170d) QbD for Generic Drugs: Modified Release Drug Products	22
<i>Andre Raw</i>	
(170e) QbD in the Generic Pharmaceutical Industry: Anticipating Its Effects On the Development of Immediate and Modified Release Dosage Forms	23
<i>John Kirsch</i>	
(170f) QbD in Generic Drug Development: PAT Application	24
<i>Yanming Zu, Yi Luo, Salah U. Ahmed</i>	
(170g) QbD for Generic Drugs: Oral Suspensions	25
<i>Umesh Pai</i>	
(209a) QbD and the Transition From Wyeth to Pfizer for API Small-Molecule Development and Manufacture	31
<i>John L. Dillon</i>	
(209b) Advancing the Abbott Pipeline	32
<i>Howard E. Morton</i>	
(209c) Commercialization and Quality by Design: Towards An Improved Model for Pharmaceutical Development, Launch and Supply	33
<i>Michael P. Thien</i>	
(209d) Creating a Capabilities Driven Organization: Efficient Design of API Processes	36
<i>Bret E. Huff</i>	
(299a) Question-Based Review for Generic Drugs	37
<i>Lawrence Yu</i>	

(299b) QbD at the Boundary	38
<i>San Kiang</i>	
(299c) Implementing Quality by Design (QbD) for New Drug Products - A Regulatory Perspective	39
<i>Sharmista Chatterjee</i>	
(299d) The Heartburn Associated with Implementing Quality by Design Principles	40
<i>Kevin D. Seibert</i>	
(299e) Quality by Design and Mechanistic Models of Pharmaceutical Unit Operations	41
<i>Pavol Rajniak, Shane Grosser, John Lepore, Rey Chern, Eric Ahuja</i>	
(299f) Quality-by-Design (QbD): Integration of Real-Time PAT Process Monitoring and off-Line Product Characterization to Explore the Linkage Between a Pharmaceutical Process and Product	42
<i>Huiquan Wu, Mansoor A. Khan</i>	
(299g) Quality-by-Design (QbD) Round Table Discussion	43
<i>Christine Seymour, Huiquan Wu</i>	
(358a) Design Space and QbD: It's All about the (Stochastic) Distributions	44
<i>John J. Peterson</i>	
(358b) Optimization-Based Design Space Characterization Using First-Principles Models	76
<i>Constantinos C. Pantelides, Mark Pinto, Sean K. Bermingham</i>	
(358c) Accelerated Development and Improved Process Operations Using Advanced Multivariate Latent Variable Modeling	77
<i>Salvador Garcia-Munoz</i>	
(358d) A Perspective on Batch Versus Continuous Processing	78
<i>Christine Seymour</i>	
(358e) Quality by Design and Multivariate Process Representations	79
<i>Jose Cardoso Menezes</i>	
(424a) A Quality Systems Approach to the Product Quality Risk Management Lifecycle	80
<i>Steven Wolfgang</i>	
(424b) Implementation of a Normalization Risk Assessment Tool to Link Design Space Inputs	81
<i>Diana S. Hou, Neil Macphail, Edward J. Smith, Jennifer Ho, Alanna Cleary</i>	
(424c) Risk Based Roadmap for the Approval of Biosimilar Biologics	82
<i>Henry Y. Wang</i>	
(424d) An Example of Quality Risk Management Over Product Lifecycle	83
<i>T. Kourti</i>	
(424e) Quality by Design in Generic Drug Development: Process Development and Quality Risk Management	84
<i>Sivakumar R. Vaithiyalingam</i>	
(424f) A High Throughput, Parallel, Microscale, Fully Automated Approach to Biologics Formulation Development and Stress Test Studies	85
<i>Eric Carlson, Byeong Chang, Steve Cypes, Steve Lambert</i>	
(424g) CFD Simulations for Scale up of Wet Milling in High Shear Mixers	86
<i>Meng Yang, Richard V. Calabrese</i>	
(424h) Optimizing and Controlling High Value Processes Using the Principles of Quality-by-Design (QbD) Advanced Tools Such as Real-Time in-Situ Particle Characterization, in-Situ Mid-Infrared Spectrometry, and Reaction Calorimetry	87
<i>Leen Schellekens, Des O'Grady, Jeffrey Sherman</i>	
(445a) Optimal Material Selection for Oral Dosage Development and Manufacture Using Optimization Techniques and Multivariate Latent Variable Models	88
<i>Salvador Garcia-Munoz, Jose Mercado, Israel Cotto, Victor Ruiz, Ivelisse Colon-Rivera, Denise Rivkees, Josh Shockey, Matt Shaffer, Leah Appel</i>	
(445b) Applications of Genetic Algorithms for Variable Selection in Pharmaceutical Development	90
<i>Jose E. Tabora, Jacob Albrecht, James Bergum, Amanda Rogers, Victor Rosso</i>	
(445c) Multivariate Analysis of Historical Process Data for Monitoring, Control and Scale-up	91
<i>Samarth Rathore, David Reed, Marc Champagne</i>	
(445d) Estimation of Active Pharmaceutical Ingredients Content In Blending Process for Drug Products Manufacturing	92
<i>Sanghong Kim, Hiroshi Nakagawa, Manabu Kano, Shinji Hasebe</i>	
(445e) Desensitizing near-Infrared Calibration Models for Physical Interferences in Tablets During Formulation/Process Development	101
<i>Benoit Igne, Zhenqi Shi, Carl A. Anderson, James K. Drennen III</i>	
(445f) Imaging Pharmaceutical Fluidised Bed Multi-Processes with Electrical Capacitance Tomography	103
<i>Haigang Wang, Lubomir Gradinarsky, Staffan Folestad, Proctor Ian, Wuqiang Yang</i>	

(510a) Quality-by-Design (QbD): Integration of Design of Experiments (DOE) and Real-Time PAT Monitoring for Pharmaceutical Powder Blending Process Evaluation	114
<i>Huiquan Wu, Mansoor A. Khan</i>	
(510b) Raman Spectroscopy Combined with Small and Wide Angle X-Ray Scattering as a Non Destructive Quality Control Tool for Powder Compression Analytics in Pharmaceutical Applications	115
<i>Nicolas Heigl, Johannes G. Khinast</i>	
(510c) On-Line Monitoring of Roller Compaction Ribbon Density Using NIR Spectroscopy	116
<i>Ryan McCann, Ariel Muliadi, Janne Paaso, James Litster, Rodolfo Pinal</i>	
(510d) Real-Time Monitoring of Pharmaceutical Manufacturing Processes with a Multiplexed Optical Fiber Probe NIR-Setup	118
<i>Nikolaus Balak, Daniel M. Koller, Johannes Khinast</i>	
(510e) On-Line Blend Monitoring of Pharmaceutical Materials Using Multiple NIR Sensors	119
<i>Benoit Igne, Zhenqi Shi, Carl A. Anderson, James K. Drennen III</i>	
(510f) Drying Mechanism and Aggregate Formation of API	120
<i>Daniel Hsieh, Joshua Engstrom, Deniz Erdemir, Steven Chan, Steve S. Y. Wang, Shih-Ying Chang, Chiajen Lai, San Kiang</i>	
(510g) Real-Time Monitoring of Continuous Processes with Spectroscopic PAT-Tools	121
<i>Daniel M. Koller, Nikolaus Balak, Simon D. Fraser, Johannes G. Khinast</i>	
(621b) An Integrated Quality-by-Design (QbD) Approach towards Design Space Definition of Key Unit Operations In the Manufacturing of Solid Dosage Forms by Discrete Element Method (DEM) and Computational Fluid Dynamics (CFD) Simulation	122
<i>Siegfried Adam, Daniele Suzzi, Stefan Radl, Gregor Toschkoff, Charles Radeke, Thomas Hoermann, Marco Iannuccelli, Johannes Khinast</i>	
(621c) A Science and Risk-Based Approach to Design Space Drug Product Development	124
<i>Indra Neil Mukherjee, Neil Macphail, Catherine Diimmel, Mitchell Colletto, Eric Seymour</i>	
(621d) Spray Drying Process Design: Establishing Links Between Process Parameters and Product Performance	125
<i>Scott R. Ellis</i>	
(621e) Drop-On-Demand Dispensing of Pharmaceutical Suspensions: Correlation of Material Attributes and Operating Conditions to Process Performance	155
<i>Sara Holt, Paul Takhistov, Fernando Muzzio</i>	
(621f) Can A Design Space Be Built On Material Attributes Alone?	156
<i>James N. Michaels, Holly Bonsignore, Buffy L. Hudson-Curtis, Steven Laurenz, Homer Lin, Thomas Mathai, Girish Pande, Ashlesh Sheth, Omar Sprockel</i>	
(621g) Impact of API Particle Size On a Sustained Release Oral Tablet Formulation	157
<i>Sarina G. Harris Ma, Derrick Kim, Chen Mao, Laura Maurer, Sami Karaborni</i>	
(673a) A Lab-Scale Investigation Into Drying of An Active Pharmaceutical Ingredient to Gain Process Understanding for Application in Full-Scale Manufacture	158
<i>Holly Shearer</i>	
(673b) Pragmatic Application of Crystallization Design Basics for a Pharmaceutical Compound	159
<i>James Wertman, Megan Ackers, Philip Dell'Orco</i>	
(673c) A Risk-Based Approach to the Application of Biocatalysis for Manufacture of Small Molecule APIs	160
<i>Stuart Goodall, John Wong, Gregory Finch, Timothy J. Watson, Deborah Finco, Ned Mozier</i>	
(673d) Modeling Approach for the Scale-up of a Reactive Distillation System	161
<i>Isabel Figueroa, Shekhar Viswanath</i>	
(673e) Sequential Design of Experiments for Design Space Definition of the Crystallization of An Active Pharmaceutical Ingredient	162
<i>Eric Sirota, James P. Corry, Ralph Calabria, Paul James, Shane Grosser, Luke Schenck, Aaron Cote, Aaron Moment</i>	
(673f) Plantwide Dynamic Simulation and Model-Based Control of a Continuous Pharmaceutical Process	163
<i>Dimitrios I. Gerogiorgis</i>	
(673g) Quality Control by QbD-Guided Optimization of Reaction and Crystallization	166
<i>Evan T. Barlow, Frederic Buono, Thomas Laporte, Jaan Pesti, Lori Spangler</i>	
(697a) Computational Predictive Models Applied to Scale-up of Solid Oral Drug Products	167
<i>Mary T. Am Ende, Rahul Bharadwaj, Pankaj Doshi, Salvador Garcia-Munoz, William R. Ketterhagen, Andrew Prpich</i>	
(697b) Achieving QM Accuracy at a Fraction of Computational Cost: Lattice Energy Minimization of Organic Crystals Containing Highly Flexible Molecules	168
<i>Andrei V. Kazantsev, Panagiotis Karamertzanis, Claire S. Adjiman, Constantinos C. Pantelides</i>	

(697c) Applications of Model-Based Quality by Design for Reaction Engineering	169
<i>Stephen A. Guzikowski, James S. Bergum, Michael P. Cassidy, Chiajen J. Lai, Dong Lin, Sunil S. Patel, Michael E. Randazzo, Thomas M. Razler, Emily A. Reiff, Victor W. Rosso, Jose Tabora, John E. Thornton, Xuejun Xu</i>	
(697d) Mixture DOE and Design Space	170
<i>Patrick J. Whitcomb, Mark J. Anderson</i>	
(697e) A Framework for in-Silico Formulation Design and Optimization Using Multivariate Latent Variable Regression Methods	175
<i>Salvador Garcia-Munoz, Mark Polizzi</i>	
(697f) Modelling and Informatics Challenges IN Film-BASED Drug Formulations and Manufacture.....	177
<i>Maria Elisa Luque, Bo Zhou, Rodolfo Pinal, G. V. Reklaitis, Venkat Venkatasubramanian</i>	
(697g) Quality by Design Approach to Pharmacokinetic Modeling. A Case Study On Cyclosporin A.....	178
<i>Eric Lueshen, Cierra Hall, Andrej Mošat, Andreas A. Linninger</i>	
Author Index	